ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ALPIX Pixium Vision SA

0.3764
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pixium Vision SA EU:ALPIX Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.3764 0.25 0.25 0.00 01:00:00

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings

17/01/2024 6:00am

GlobeNewswire Inc.


Pixium Vision (EU:ALPIX)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Pixium Vision Charts.

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings

Paris, France, January 17, 2024 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the Company as soon as it becomes aware of it.

Pixium draws investors’ attention to the fact that, given the price offered by the prospective buyer and the Company’s level of indebtedness, the sale proceeds received in the event of a favourable decision by the Commercial Court will not allow a total or partial reimbursement of shareholders.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information: http://www.pixium-vision.com/fr

Follow us on @PixiumVision; www.facebook.com/pixiumvision

               www.linkedin.com/company/pixium-vision  

Contacts

Investor RelationsPixium VisionOffer NonhoffChief Financial Officerinvestors@pixium-vision.comMedia Relations Rose Piquante ConsultingSophie BaumontSophie.baumont@rosepiquante-consulting.com+33 6 27 74 74 49

 

Attachment

  • Pixium - PR postponement of the Court's decision - 16.01.2024

1 Year Pixium Vision Chart

1 Year Pixium Vision Chart

1 Month Pixium Vision Chart

1 Month Pixium Vision Chart